GSK plc and Bioversys AG have described the development of ethionamide boosters...

Spero Therapeutics Inc. has come out swinging after a U.S. FDA rejection for its oral antibiotic, tebipenem Hbr, picking up a potential $600 million licensing deal with pharma giant GSK plc after agreeing on a plan with the regulator to revive the drug.

Researchers from Consejo Superior de Investigaciones Cientificas (CSIC) and affiliated organizations presented the discovery of a novel series of compounds acting as Ebola virus (EBOV) entry inhibitors.

An antibody that protects babies against respiratory syncytial virus (RSV) from Astrazeneca Ltd. and Sanofi SA was among a string of recommendations from the EMA’s Committee for Medicinal Products for Human Use, paving the way for approval within the next few months and a potential launch in 2023.

Scientists from the University of Queensland have created a new antibiotic that can neutralize various gram-positive bacteria in mice, including major threats such as methicillin-resistant Staphylococcus aureus (MRSA). In a recent study, published in the Sept. 14, 2022, issue of Science Translational Medicine, the new compound outperformed the approved antibiotic vancomycin, and destroyed tough-to-eradicate bacterial biofilms while prompting a low rate of resistance.

Researchers from Anacor Pharmaceuticals Inc. and Pfizer Inc. have published preclinical data for the novel benzoxaborole prodrug AN-15368, being developed for the treatment of Chagas disease.

The development of needle-free mucosal vaccines for SARS-CoV-2 would be advantageous, potentially reducing viral acquisition as well as transmission.